[18F]-DPA-714 PET to detect brain inflammation in autoimmune encephalitis
Official title: Is [18F]-DPA-714 PET a Good Marker of Neuroinflammation in Autoimmune Encephalitis?
Run by University Hospital, Toulouse · NCT07488117 · Data updated 2026-11-12
This test tries to see if [18F]-DPA-714 PET scans can detect brain inflammation in adults newly diagnosed with autoimmune encephalitis.
Quick facts
| Phase | Phase 2 |
|---|---|
| Study type | Interventional |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | University Hospital, Toulouse Academic / other |
| Locations | 1 site (Toulouse) |
| Status | Recruiting |
| Started | March 31, 2026 |
| Main results expected | June 2027 |
| Study ends | January 2028 |
| Registry record updated | May 11, 2026 |
| Trial ID | NCT07488117 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults 18–80 years old with a recent (under 6 months) diagnosis meeting 'possible' autoimmune encephalitis criteria with identified antibodies, who have not received second-line immunosuppressive therapy and who have a high or mixed TSPO binding affinity, are the intended participants.
✕Probably not a fit
People who are pregnant, have MRI contraindications, have received second-line immunosuppression, have low TSPO binding affinity, have a known allergy to [18F]-DPA-714, or have paraneoplastic syndrome after immune checkpoint inhibitors are unlikely to benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
Autoimmune encephalitis is a heterogeneous group of disorders whose diagnosis can be difficult using MRI and CSF alone. This study uses a 60-minute dynamic PET scan after injection of [18F]-DPA-714, a tracer that binds the 18-kDa translocator protein (TSPO) linked to neuroimmune activity. Participants will receive clinical evaluation, MRI, and lumbar puncture as part of standard care, and PET results will be compared with healthy controls and conventional biomarkers. The goal is to characterize in vivo neuroinflammation at disease onset and determine whether PET adds diagnostic information.
Why it matters
Potential benefit: If successful, this imaging could give clinicians a more direct way to see brain immune activity and help start the right treatment sooner.
How similar studies have gone: TSPO-targeted PET tracers have shown promising but variable results in other neuroinflammatory disorders, and using [18F]-DPA-714 specifically for autoimmune encephalitis is relatively new.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age 18-80 years; * meeting clinical criteria for "possible" AE with identified antibodies; * newly diagnosed with symptoms \<6 months; * no second-line immunosuppressive treatment; * high or mixed TSPO binding affinity phenotype. Exclusion Criteria: * Pregnant women; * contraindications to MRI; * known allergic reaction to \[18F\]-DPA-714; legal protection measure; * paraneoplastic syndrome following immune checkpoint inhibitor therapy.
Where it's running
-
University Hospital
Toulouse, France Recruiting
Study contacts
- Study coordinator: Marie Rafiq, MD
- Email: rafiq.m@chu-toulouse.fr
- Phone: +33 561779491
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Daily vs alternate-day plasma exchange in pediatric autoimmune encephalitis
This study tests whether giving plasma exchange on consecutive days is better than every other day for kids with autoimmune encephalitis.
-
OPM-MEG Brain Imaging in Young People with Immune- and Non-immune Related Neurological Disease
Researchers will test a fancy, child-friendly brain scan (OPM-MEG) to see how brain networks look in kids with autoimmune or other brain diseases and how that relates to their symptoms.
-
QH103 (universal CD19 CAR-γδT) cell injections for relapsed or treatment‑resistant antibody-driven neurological autoimmune diseases
This Phase 1 test will see if QH103 (universal CD19 CAR-γδT) cell injections are safe and tolerated in adults with relapsed or treatment‑resistant antibody-mediated neurological diseases such as MS, NMOSD, AE, CIDP, or MG.
-
CD19/BCMA-targeted UCAR-T for neurological autoimmune disorders
This trial tests an off-the-shelf CD19/BCMA UCAR-T cell therapy with lymphodepletion in adults with relapsing or treatment-resistant MS, myasthenia gravis, CIDP, or autoimmune encephalitis.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.